詳細ガイド 近日公開
Tirzepatide Dose Calculatorの包括的な教育ガイドを準備中です。ステップバイステップの解説、数式、実例、専門家のヒントをお届けしますので、もうしばらくお待ちください。
The Tirzepatide Dose Escalation Calculator models the FDA-approved titration schedule for tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Unlike semaglutide which acts on a single receptor, tirzepatide simultaneously activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing greater weight loss and glycemic improvement in head-to-head comparisons. The tirzepatide dose escalation follows a 6-step schedule with more dose options than semaglutide: 2.5 mg for weeks 1 to 4, then 5 mg for weeks 5 to 8, with optional further escalation through 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg. The minimum maintenance dose is 5 mg, and the decision to escalate beyond 5 mg is based on individual response and tolerability. This flexibility distinguishes tirzepatide dosing from the fixed Wegovy escalation, allowing physicians to personalize the dose to each patient's needs. The SURMOUNT clinical trial program demonstrated that tirzepatide produces dose-dependent weight loss: 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg over 72 weeks. For type 2 diabetes, the SURPASS trials showed A1C reductions of 1.87 to 2.07 percentage points across the dose range. Understanding the dose-response relationship helps patients and prescribers make informed decisions about whether to continue escalating or maintain at a lower dose that balances efficacy against side effect burden. This calculator serves patients tracking their titration progress, physicians selecting the optimal dose for individual patients, pharmacists verifying prescription accuracy during dose transitions, and insurance utilization reviewers confirming that dose escalation follows the approved schedule. It also helps patients understand that tirzepatide offers more dose flexibility than semaglutide, with six possible maintenance doses rather than one fixed target.
Weekly Dose at Week W = Titration Schedule Lookup(W), where the standard schedule is: Weeks 1-4 = 2.5 mg, Weeks 5-8 = 5.0 mg, Weeks 9-12 = 7.5 mg (optional), Weeks 13-16 = 10 mg (optional), Weeks 17-20 = 12.5 mg (optional), Weeks 21+ = 15 mg (optional maximum). Minimum maintenance = 5 mg. For a worked example: a patient at Week 14 on 10 mg has received a cumulative dose of (2.5 x 4) + (5.0 x 4) + (7.5 x 4) + (10 x 2) = 10 + 20 + 30 + 20 = 80 mg total. If they escalate to 12.5 mg at Week 17, their projected maintenance dose of 15 mg would be reached at Week 21.
- 1Select the tirzepatide brand and indication. Mounjaro is prescribed for type 2 diabetes mellitus, while Zepbound is prescribed for chronic weight management. Both brands use the same molecule and identical dose escalation schedule, but they have different NDC codes, pricing, insurance coverage, and prior authorization requirements. The calculator adjusts its insurance and cost estimates based on which brand is selected.
- 2Enter your treatment start date or current week number. The calculator determines your position in the titration schedule and identifies your current prescribed dose. For patients who have been on tirzepatide for an extended period at a stable dose, entering the maintenance dose directly allows the calculator to skip the titration phase and focus on dose optimization recommendations.
- 3Review the recommended dose escalation timeline. Unlike Wegovy, which has a single target maintenance dose of 2.4 mg, tirzepatide offers physician discretion at each step above 5 mg. The calculator displays the dose-response data showing incremental weight loss at each dose level (approximately 3 to 5 additional percentage points between 5 mg and 15 mg) alongside the incremental side effect risk, helping patients and providers weigh the benefit of further escalation against tolerability.
- 4The calculator identifies the specific pen device for your current dose. Tirzepatide pens are single-dose, pre-filled devices with color-coded labels for each dose strength: 2.5 mg (gray), 5 mg (purple), 7.5 mg (brown), 10 mg (blue-green), 12.5 mg (pink), and 15 mg (blue). Each dose transition requires a new prescription for the corresponding pen, and the pharmacy must order the correct NDC code.
- 5For patients experiencing side effects, the calculator models alternative titration strategies. Common approaches include extended intervals (8 weeks at each dose instead of 4), dose reduction (stepping back from a dose that caused intolerable side effects), and dose capping (establishing a maximum tolerated dose below 15 mg). The calculator recalculates the projected timeline and expected efficacy under each alternative strategy, showing patients that a lower dose may still produce clinically meaningful results.
- 6The supply management module tracks pen inventory and alerts patients when to request refills. Because tirzepatide has experienced intermittent supply constraints since its launch, the calculator also flags current shortage status by dose strength and suggests contingency strategies such as requesting a 90-day supply when available or identifying alternative pharmacies with stock. Early refill requests, placed 2 to 3 weeks before the pen is needed, can prevent treatment gaps.
- 7The output includes a comparison with the equivalent semaglutide dose at each titration step, allowing patients considering a switch between medications to understand the dose equivalency and potential need for additional titration. For example, a patient on tirzepatide 10 mg who switches to semaglutide would likely start at semaglutide 1.7 mg or 2.4 mg based on approximate receptor occupancy equivalence, though no formal dose-conversion guideline exists.
This patient is progressing through the titration on schedule. At 7.5 mg, clinical trial data predicts approximately 17 percent body weight loss at steady state. The patient and physician can decide whether the additional 3 to 4 percentage points of weight loss from escalating to 15 mg justifies the potential increase in gastrointestinal side effects.
Not all patients need to reach 15 mg. At 10 mg, this patient with type 2 diabetes is achieving excellent glycemic control and substantial weight loss. The SURPASS-3 trial showed that the difference in A1C reduction between 10 mg and 15 mg was only 0.1 percentage points, suggesting minimal additional glycemic benefit from further escalation.
Dose intolerance is common and does not mean the medication has failed. Stepping back to the last tolerated dose, allowing extra time for adaptation, and re-attempting the higher dose with supportive measures (anti-nausea medication, dietary modifications) succeeds in approximately 60 to 70 percent of cases on the second attempt.
A patient targeting the maximum dose of 15 mg must progress through all 6 dose levels at 4-week intervals, taking 20 weeks (approximately 5 months) to complete the titration. This is 4 weeks longer than the Wegovy titration to 2.4 mg because tirzepatide has 6 steps versus 5.
Endocrinologists managing type 2 diabetes use the tirzepatide dose calculator to individualize dose selection based on glycemic targets. Because tirzepatide offers six dose options, physicians can titrate to the minimum effective dose that achieves the patient's A1C target while minimizing side effects. A patient who reaches A1C below 7 percent on tirzepatide 7.5 mg may not need further escalation, saving cost and reducing side effect exposure compared to automatically escalating to the maximum dose.
Weight management specialists use the dose-response data embedded in the calculator to have informed discussions with patients about the trade-off between additional weight loss and side effect risk at higher doses. Showing a patient that 10 mg produces 19.5 percent body weight loss versus 20.9 percent at 15 mg helps them understand that the incremental benefit of the last two dose escalations (approximately 1.4 additional percentage points) may not justify the increased gastrointestinal burden for their individual situation.
Pharmaceutical benefit managers and insurance plan designers use dose escalation patterns to design utilization management programs and predict pharmacy costs. Since tirzepatide's cost is the same regardless of dose strength, the financial question is not which dose is cheapest but rather how long patients spend in the titration phase (when some payers use lower-cost starter programs) versus the maintenance phase. Understanding typical dose distributions in real-world populations helps actuaries predict per-member costs.
Patients themselves use the calculator as a self-management tool to track their progress through the titration, anticipate upcoming dose changes, and prepare questions for their provider visits. The visual timeline format helps patients understand that the dose escalation is a planned, temporary phase rather than an indefinite series of changes, reducing anxiety about the process and improving adherence during the critical first 5 months of therapy.
Patients with a history of pancreatitis require careful monitoring during
Patients with a history of pancreatitis require careful monitoring during tirzepatide dose escalation because GLP-1 receptor agonists carry a warning for acute pancreatitis. While the absolute risk is low (less than 0.5 percent in clinical trials), patients with prior pancreatitis episodes are at higher baseline risk. Many clinicians use a slower titration pace (8-week intervals) for these patients and monitor amylase and lipase levels at each dose transition, pausing escalation if enzyme levels rise above twice the upper limit of normal.
Patients concurrently taking insulin require coordinated dose adjustment during tirzepatide escalation.
As tirzepatide stimulates endogenous insulin secretion and improves insulin sensitivity, exogenous insulin requirements decrease substantially. The FDA label recommends reducing the insulin dose by 20 percent when starting tirzepatide to prevent hypoglycemia, with further reductions guided by blood glucose monitoring. The calculator includes an insulin co-management module that suggests insulin dose adjustments at each tirzepatide dose transition.
Patients with gastroparesis (delayed gastric emptying) present a special
Patients with gastroparesis (delayed gastric emptying) present a special consideration because tirzepatide slows gastric emptying as part of its mechanism of action. In patients who already have gastroparesis, this effect can worsen symptoms including bloating, early satiety, nausea, and vomiting. These patients typically require slower titration (8 to 12 week intervals), smaller meals, and may tolerate only the lower dose range (5 to 7.5 mg). The calculator flags gastroparesis as a risk factor and adjusts the recommended titration pace.
| Dose | Pen Color | Mean %BWL | Mean A1C Change | Nausea Rate | Discontinuation Rate |
|---|---|---|---|---|---|
| 2.5 mg (starting) | Gray | N/A (titration only) | N/A | N/A | N/A |
| 5 mg | Purple | 15.0% | -1.87%* | 24% | 4.3% |
| 7.5 mg | Brown | ~17% (interpolated) | ~-1.95%* | ~28% | ~5% |
| 10 mg | Blue-green | 19.5% | -1.93%* | 29% | 6.6% |
| 12.5 mg | Pink | ~20% (interpolated) | ~-2.0%* | ~31% | ~7% |
| 15 mg | Blue | 20.9% | -2.07%* | 33% | 6.2% |
| Placebo | N/A | 3.1% | -0.09% | 9% | 2.6% |
What is the tirzepatide dose escalation schedule?
Tirzepatide starts at 2.5 mg weekly for 4 weeks, then increases to 5 mg weekly (the minimum maintenance dose). From there, doses can be increased in 2.5 mg increments every 4 weeks through 7.5 mg, 10 mg, 12.5 mg, and up to the maximum of 15 mg weekly. The key difference from semaglutide is that escalation beyond 5 mg is optional and based on individual response, rather than following a fixed protocol to a single target dose.
Do I have to go all the way to 15 mg?
No. The minimum effective maintenance dose of tirzepatide is 5 mg, and many patients achieve excellent results without reaching 15 mg. In the SURMOUNT-1 trial, patients on tirzepatide 5 mg lost an average of 15 percent of body weight, which is comparable to the maximum dose of semaglutide 2.4 mg (14.9 percent in STEP 1). Your physician will assess your response at each dose level and recommend further escalation only if the clinical benefit justifies the potential increase in side effects.
How is tirzepatide different from semaglutide?
Tirzepatide is a dual-agonist that activates both the GIP and GLP-1 receptors, while semaglutide activates only the GLP-1 receptor. This dual mechanism is believed to produce greater weight loss and glycemic improvement. In the SURMOUNT-5 head-to-head trial, tirzepatide 15 mg produced 20.2 percent body weight loss versus 13.7 percent for semaglutide 2.4 mg. Tirzepatide also offers more dose flexibility with six possible maintenance doses versus semaglutide's one (for Wegovy) or three (for Ozempic).
What side effects should I expect during dose escalation?
The most common side effects are gastrointestinal: nausea (affected 24 to 33 percent of patients in SURMOUNT-1 depending on dose), diarrhea (17 to 23 percent), constipation (11 to 17 percent), and vomiting (7 to 12 percent). These side effects are most pronounced during the first 2 to 4 weeks after each dose increase and typically improve with continued use. The incidence generally increases with dose, which is another reason the gradual titration is important. Serious side effects including pancreatitis are rare (less than 0.5 percent).
Can I switch between Mounjaro and Zepbound?
Mounjaro and Zepbound contain identical tirzepatide at the same dose strengths, so switching between them does not require dose adjustment. The reason for switching is typically insurance-related: a patient whose insurance covers Mounjaro for diabetes but not Zepbound for weight management (or vice versa) might switch brands if their indication or coverage changes. The transition is seamless at the same dose level, but the pharmacy will need a new prescription for the different brand NDC code.
How should I inject tirzepatide?
Tirzepatide is injected subcutaneously (under the skin) once weekly, in the abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy (thickening of the tissue). The pre-filled pen has a hidden needle that deploys automatically when pressed against the skin. Inject on the same day each week, at any time of day, with or without food. If you need to change your injection day, you can do so as long as at least 3 days (72 hours) have passed since your last dose.
プロのヒント
If you are tolerating your current dose well but want to optimize weight loss before deciding to escalate, focus on maximizing lifestyle factors at your current dose for a full 4 to 8 weeks: ensure protein intake is at least 1.2 g per kg of body weight, perform resistance training 2 to 3 times per week, and maintain 7 to 9 hours of sleep. These complementary strategies can add 2 to 5 percentage points of additional weight loss beyond what the medication alone provides, potentially achieving your goal without the side effect risk of a higher dose.
ご存知でしたか？
Tirzepatide was designed by Eli Lilly scientists to mimic two gut hormones simultaneously: GLP-1 and GIP. Ironically, early research on GIP suggested it might promote weight gain rather than weight loss, leading many scientists to dismiss it as an obesity target. Eli Lilly's counterintuitive bet that co-activating both receptors would produce superior weight loss paid off spectacularly, with tirzepatide producing the largest weight loss of any medication ever tested in phase III clinical trials as of 2023.